Published in N Engl J Med on September 11, 1997
Effects of Nitric Oxide and Nitroglycerin in Patients With Sickle Cell Anemia | NCT00001716
Hydoxycarbamide and L-Carnitine Therapy in Sickle Cell Anemia | NCT05081349
DNA polymorphisms at the BCL11A, HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease. Proc Natl Acad Sci U S A (2008) 4.46
In vitro microvessels for the study of angiogenesis and thrombosis. Proc Natl Acad Sci U S A (2012) 3.61
Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. Blood (1999) 2.66
Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease. N Engl J Med (2016) 2.62
Label-free cell separation and sorting in microfluidic systems. Anal Bioanal Chem (2010) 2.60
In vitro modeling of the microvascular occlusion and thrombosis that occur in hematologic diseases using microfluidic technology. J Clin Invest (2011) 1.89
Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease. Proc Natl Acad Sci U S A (2010) 1.72
Sickle cell vasoocclusion and rescue in a microfluidic device. Proc Natl Acad Sci U S A (2007) 1.69
Genetic diminution of circulating prothrombin ameliorates multiorgan pathologies in sickle cell disease mice. Blood (2015) 1.43
Cardiopulmonary complications of sickle cell disease: role of nitric oxide and hemolytic anemia. Hematology Am Soc Hematol Educ Program (2005) 1.36
Pulmonary complications of sickle cell disease. Am J Respir Crit Care Med (2012) 1.35
A biophysical indicator of vaso-occlusive risk in sickle cell disease. Sci Transl Med (2012) 1.32
Understanding the shape of sickled red cells. Biophys J (2004) 1.32
Cardiovascular abnormalities in sickle cell disease. J Am Coll Cardiol (2012) 1.31
Amplified expression profiling of platelet transcriptome reveals changes in arginine metabolic pathways in patients with sickle cell disease. Circulation (2007) 1.29
Therapeutic levels of fetal hemoglobin in erythroid progeny of β-thalassemic CD34+ cells after lentiviral vector-mediated gene transfer. Blood (2010) 1.21
Mutations and polymorphisms in hemoglobin genes and the risk of pulmonary hypertension and death in sickle cell disease. Am J Hematol (2008) 1.15
Cytokine-mediated increases in fetal hemoglobin are associated with globin gene histone modification and transcription factor reprogramming. Blood (2009) 1.15
Inhaled nitric oxide augments nitric oxide transport on sickle cell hemoglobin without affecting oxygen affinity. J Clin Invest (1999) 1.15
Pulmonary manifestations of sickle cell disease. Postgrad Med J (2003) 1.10
Nitric oxide and arginine dysregulation: a novel pathway to pulmonary hypertension in hemolytic disorders. Curr Mol Med (2008) 1.07
Genetic complexity in sickle cell disease. Proc Natl Acad Sci U S A (2008) 1.04
Anesthetic management of a patient with sickle cell disease for common bile duct exploration. J Anaesthesiol Clin Pharmacol (2011) 1.04
Vasculopathy and pulmonary hypertension in sickle cell disease. Am J Physiol Lung Cell Mol Physiol (2014) 1.03
Vascular risk assessment in patients with sickle cell disease. Haematologica (2011) 1.03
Sickle-cell disease in California: a population-based description of emergency department utilization. Pediatr Blood Cancer (2010) 1.02
The mononuclear phagocyte system in homeostasis and disease: a role for heme oxygenase-1. Antioxid Redox Signal (2014) 1.01
Statistical dynamics of flowing red blood cells by morphological image processing. PLoS Comput Biol (2009) 0.99
Placenta growth factor (PlGF), a novel inducer of plasminogen activator inhibitor-1 (PAI-1) in sickle cell disease (SCD). J Biol Chem (2010) 0.98
Sickle cell disease: new opportunities and challenges in Africa. ScientificWorldJournal (2013) 0.97
Sickle Cell Disease in the Post Genomic Era: A Monogenic Disease with a Polygenic Phenotype. Genomics Insights (2009) 0.96
The role of infection in the pathogenesis of vaso-occlusive crisis in patients with sickle cell disease. Mediterr J Hematol Infect Dis (2011) 0.96
MP4CO, a pegylated hemoglobin saturated with carbon monoxide, is a modulator of HO-1, inflammation, and vaso-occlusion in transgenic sickle mice. Blood (2013) 0.95
MicroRNA-96 directly inhibits γ-globin expression in human erythropoiesis. PLoS One (2011) 0.95
Pulmonary hypertension associated with chronic hemolytic anemia and other blood disorders. Clin Chest Med (2013) 0.95
Arginase in retinopathy. Prog Retin Eye Res (2013) 0.94
Total antioxidants status and some hematological values in sickle cell disease patients in steady state. J Natl Med Assoc (2007) 0.94
Effect of chain chirality on the self-assembly of sickle hemoglobin. Biophys J (2012) 0.94
Venous thromboembolism incidence in the Cooperative Study of Sickle Cell Disease. J Thromb Haemost (2014) 0.94
Pathophysiological insights in sickle cell disease. Indian J Med Res (2011) 0.93
Sickle cell disease and venous thromboembolism: what the anticoagulation expert needs to know. J Thromb Thrombolysis (2013) 0.93
A human embryonic hemoglobin inhibits Hb S polymerization in vitro and restores a normal phenotype to mouse models of sickle cell disease. Proc Natl Acad Sci U S A (2002) 0.92
Biochemical and immunological mechanisms by which sickle cell trait protects against malaria. Malar J (2013) 0.92
Neutrophil sandwiches injure the microcirculation. Nat Med (2009) 0.91
The "fish-vertebra" sign. Emerg Med J (2007) 0.91
Differences in response to fetal hemoglobin induction therapy in beta-thalassemia and sickle cell disease. Blood Cells Mol Dis (2009) 0.91
Care seeking for pain in young adults with sickle cell disease. Pain Manag Nurs (2013) 0.89
Right ventricular and pulmonary function in sickle cell disease patients with pulmonary hypertension. Pediatr Cardiol (2006) 0.88
EHMT1 and EHMT2 inhibition induces fetal hemoglobin expression. Blood (2015) 0.88
Sickle-cell anemia hemoglobin: the molecular biology of the first "molecular disease"--the crucial importance of serendipity. Genetics (2004) 0.88
Selective disruption of protein aggregation by cyclodextrin dimers. Proc Natl Acad Sci U S A (2000) 0.88
Heterogeneous red blood cell adhesion and deformability in sickle cell disease. Sci Rep (2014) 0.87
Fundamentals and application of magnetic particles in cell isolation and enrichment: a review. Rep Prog Phys (2014) 0.86
Sickle cell hemoglobinopathies in district Bhopal. Indian J Hum Genet (2010) 0.86
Gene-centric association study of acute chest syndrome and painful crisis in sickle cell disease patients. Blood (2013) 0.86
Defects in postabsorptive plasma homeostasis of fatty acids in sickle cell disease. JPEN J Parenter Enteral Nutr (2007) 0.85
Gene Therapy of the β-Hemoglobinopathies by Lentiviral Transfer of the β(A(T87Q))-Globin Gene. Hum Gene Ther (2016) 0.85
Customizing the genome as therapy for the β-hemoglobinopathies. Blood (2016) 0.85
Evaluation of engraftment and immunological tolerance after reduced intensity conditioning in a rhesus hematopoietic stem cell gene therapy model. Gene Ther (2013) 0.85
Masked hypertension is prevalent in children with sickle cell disease: a Midwest Pediatric Nephrology Consortium study. Pediatr Nephrol (2012) 0.85
A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes. Haematologica (2013) 0.84
Pathological basis of symptoms and crises in sickle cell disorder: implications for counseling and psychotherapy. Hematol Rep (2010) 0.84
The isolation of an RNA aptamer targeting to p53 protein with single amino acid mutation. Proc Natl Acad Sci U S A (2015) 0.83
A phase 1/2 trial of HQK-1001, an oral fetal globin inducer, in sickle cell disease. Am J Hematol (2012) 0.83
Dietary ω-3 fatty acids protect against vasculopathy in a transgenic mouse model of sickle cell disease. Haematologica (2015) 0.82
Hydroxyurea is associated with lower prevalence of albuminuria in adults with sickle cell disease. Nephrol Dial Transplant (2013) 0.82
Platelet-neutrophil interactions under thromboinflammatory conditions. Cell Mol Life Sci (2015) 0.82
Sickle cell disease: management options and challenges in developing countries. Mediterr J Hematol Infect Dis (2013) 0.82
Hydroxyurea-Increased Fetal Hemoglobin Is Associated with Less Organ Damage and Longer Survival in Adults with Sickle Cell Anemia. PLoS One (2015) 0.81
In vivo production of type 1 cytokines in healthy sickle cell disease patients. J Natl Med Assoc (1999) 0.81
Identification of a small molecule that increases hemoglobin oxygen affinity and reduces SS erythrocyte sickling. ACS Chem Biol (2014) 0.81
Differences in the actions of some blockers of the calcium-activated potassium permeability in mammalian red cells. Br J Pharmacol (1999) 0.81
Evaluation of safety and pharmacokinetics of sodium 2,2 dimethylbutyrate, a novel short chain fatty acid derivative, in a phase 1, double-blind, placebo-controlled, single-dose, and repeat-dose studies in healthy volunteers. J Clin Pharmacol (2011) 0.81
Amelioration of murine sickle cell disease by nonablative conditioning and γ-globin gene-corrected bone marrow cells. Mol Ther Methods Clin Dev (2015) 0.80
Albuminuria correlates with hemolysis and NAG and KIM-1 in patients with sickle cell anemia. Pediatr Nephrol (2014) 0.80
Phytomedicines and nutraceuticals: alternative therapeutics for sickle cell anemia. ScientificWorldJournal (2013) 0.80
Dynamic posttranscriptional regulation of epsilon-globin gene expression in vivo. Blood (2006) 0.80
Defective lipid metabolism in sickle cell anaemia subjects in vaso-occlusive crisis. Niger Med J (2014) 0.80
Hydroxyurea with AKT2 inhibition decreases vaso-occlusive events in sickle cell disease mice. Blood (2015) 0.80
A unique cause of intestinal and splenic infarction in a sickle cell trait patient. Case Rep Surg (2013) 0.79
Pharmacological management of sickle cell disease. P T (2008) 0.79
Potentially therapeutic levels of anti-sickling globin gene expression following lentivirus-mediated gene transfer in sickle cell disease bone marrow CD34+ cells. Exp Hematol (2015) 0.79
How to reach rapid diagnosis in sickle cell disease? Iran J Pediatr (2010) 0.79
Sickle Cell Disease: Reappraisal of the Role of Foetal Haemoglobin Levels in the Frequency of Vaso-Occlusive Crisis. Ghana Med J (2015) 0.79
Effects of nitric oxide and its congeners on sickle red blood cell deformability. Transfusion (2015) 0.78
Sickle cell protection from malaria. Hematol Rep (2011) 0.78
Red blood cell indices and prevalence of hemoglobinopathies and glucose 6 phosphate dehydrogenase deficiencies in male Tanzanian residents of Dar es Salaam. Int J Mol Epidemiol Genet (2014) 0.78
USING LIVED EXPERIENCES OF ADULTS TO UNDERSTAND CHRONIC PAIN: SICKLE CELL DISEASE, AN EXEMPLAR. Imanagers J Nurs (2011) 0.77
FOETAL HAEMOGLOBIN (HbF) STATUS IN ADULT SICKLE CELL ANAEMIA PATIENTS IN IBADAN, NIGERIA. Ann Ib Postgrad Med (2010) 0.77
Genomics and pain research in sickle cell disease: an explanation of heterogeneity? ISRN Nurs (2011) 0.77
Inactivation of HDAC1 or HDAC2 induces gamma globin expression without altering cell cycle or proliferation. Am J Hematol (2015) 0.77
Liver stiffness increases acutely during sickle cell vaso-occlusive crisis. Am J Hematol (2013) 0.77
Sickle cell disease (SCD), iNKT cells, and regadenoson infusion. Trans Am Clin Climatol Assoc (2012) 0.76
Updated Mechanisms of Sickle Cell Disease-Associated Chronic pain. Transl Perioper Pain Med (2015) 0.76
Biomechanics and biorheology of red blood cells in sickle cell anemia. J Biomech (2016) 0.76
Increased Red Blood Cell Stiffness Increases Pulmonary Vascular Resistance and Pulmonary Arterial Pressure. J Biomech Eng (2016) 0.76
Antisickling and toxicological evaluation of the leaves of Scoparia dulcis Linn (Scrophulariaceae). BMC Complement Altern Med (2015) 0.76
Chemical Inhibition of Histone Deacetylases 1 and 2 Induces Fetal Hemoglobin through Activation of GATA2. PLoS One (2016) 0.76
PKCδ-targeted intervention relieves chronic pain in a murine sickle cell disease model. J Clin Invest (2016) 0.76